Predictors of blood pressure response in the SYMPLICITY HTN-3 trial

AIMS: The SYMPLICITY HTN-3 randomized, blinded, sham-controlled trial confirmed the safety of renal denervation (RDN), but did not meet its primary efficacy endpoint. Prior RDN studies have demonstrated significant and durable reductions in blood pressure. This analysis investigated factors that may...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur Heart J
Autori principali: Kandzari, David E., Bhatt, Deepak L., Brar, Sandeep, Devireddy, Chandan M., Esler, Murray, Fahy, Martin, Flack, John M., Katzen, Barry T., Lea, Janice, Lee, David P., Leon, Martin B., Ma, Adrian, Massaro, Joseph, Mauri, Laura, Oparil, Suzanne, O'Neill, William W., Patel, Manesh R., Rocha-Singh, Krishna, Sobotka, Paul A., Svetkey, Laura, Townsend, Raymond R., Bakris, George L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2015
Soggetti:
FASTTrack Clinical Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4301597/
https://ncbi.nlm.nih.gov/pubmed/25400162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehu441
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi